Alpha 2.0
Login Register
» Articles » PMID: 36824123

Adjuvant Intravesical Chemohyperthermia or Conventional Chemotherapy in an Era of Bacillus Calmette-Guérin Shortage for Non-muscle Invasive Bladder Cancer: The HIVEC-II Trial

Overview
Journal Indian J Urol
Specialty Urology
Date 2023 Feb 24
PMID 36824123
Authors
Priyank Bhargava
Affiliations
Soon will be listed here.
Citing Articles

Analysis of therapeutic effect of cell reduction combined with intraperitoneal thermoperfusion chemotherapy in treatment of peritoneal pseudomyxoma.

Li W, Ru X, Xuan H, Fan Q, Zhang J, Lu J World J Gastrointest Surg. 2024; 16(11):3520-3530.

PMID: 39649205 PMC: 11622075. DOI: 10.4240/wjgs.v16.i11.3520.

References
1.
Tan W, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P . Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. 2022; 83(6):497-504. DOI: 10.1016/j.eururo.2022.08.003. View
2.
Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D . Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2010; 107(6):912-8. DOI: 10.1111/j.1464-410X.2010.09654.x. View
3.
Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View
4.
Tan W, Kelly J . Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018; 15(11):667-685. DOI: 10.1038/s41585-018-0092-z. View
5.
Arends T, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F . Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol. 2016; 69(6):1046-52. DOI: 10.1016/j.eururo.2016.01.006. View